Troubled $33M drug withdrawn from Australia
After conducting an assessment, CSL has pre-empted any result from an ongoing TGA review and withdrawn a troubled drug from the Australian market.
To see the whole article, log in or create an account.
Fri, 16 Oct 2026
Connecting you with your industry every day
Other News
- 1 No fine after 'disparaging a rival' investigation
- 2 Leader flies a new flag for industry
- 3 Gene therapy rollout: Australia next in line?
- 4 Advocates fight to keep Richard Scolyer’s vision alive
- 5 Aussie GM reveals success secrets in new book
- 6 Roadblock hits plans to shore up the world's biggest drug